Oct 27, 2026 earnings call — Proteoform-focused Voyager commercialization and assay roadmap
Company reported Q3 revenue of $200,000 and now expects total 2026 revenue to exceed their prior outlook of approximately $500,000.
Revenue $0.0B (est $0.0B) · EPS $-0.12 (est $-0.14)
Key quotes
"For decades, proteomics has primarily been about telling us how much protein is present."
"To accelerate our proteoform roadmap, we effectively tripled the number of people and resources focused on proteoform development, and we set a goal of developing 20 proteoform assays by the middle of 2028."
"Based on our current trajectory, we believe our financial plans support the cash runway that extends into the first quarter of 2028."
Analyst Q&A 4
SEEDS funding and AI dataset opportunity
Q (Subbu Nambi · Guggenheim): The analyst asked for details on SEEDS funding timing, whether it is milestone-based, and the best use of the funds. He also asked about the commercial AI dataset opportunity given Nautilus's position with tau, and how the company is approaching sales for tau and oncology.
A: They said the SEEDS program is split across different institutions, led by the Buck Institute and Georgetown, and that revenue will be recognized over the four-year period as work is completed. On AI, they said proteoform assays give very precise, low-CV measurements and reveal modifications and sequence variants on single molecules, and that early evidence exists with tau and beginning work on AKT1. They said the sales team is three people (hired March and April), the pipeline today is mostly tau-related, they expect Q4 sequential revenue growth without SEEDS, and they plan to grow the commercial team in 2027.
"The proteoform assays that we are building are doing two things. They are providing an extremely high reliability, low CV, very precise measurement of what is going on with critical biomarkers in disease-relevant molecular pathways." — Sujal Patel (CEO)
Instrument launch milestones and demand
Q (Dan Brennan · TD Cowen): The analyst asked for a sense of customers, projects, and funnel pace for early access. He also asked what key milestones must happen to hit the early-2027 commercial platform launch and how customer interest might affect the launch pace.
A: Management declined to give customer counts but said the sales team rebuilt the pipeline and they expect early access services revenue to grow in Q4, with oncology assays adding customer acquisition next year. For launch, they said two key milestones are instrument launch (pricing, final specs, and pre-orders) and the actual ship in the middle of the year; they plan to ship a beta unit this year and then ship instruments, consumables, software, cloud portal, and a set of applications mid-year. They expect GA to include tau, AKT1, and a second oncology assay, with additional oncology assays and several proteoforms in early access, and they view 2027 as foundation-building and 2028 as scaling with much more content.
"One is the launch of our instrument, and that is really about getting pricing finalized, final specifications out in the world, and getting ready to take pre-orders." — Sujal Patel (CEO)
Tau early-use cases and academic funding
Q (Michael Sonntag · Leerink): The analyst asked what use cases customers are running with early-access tau. He also asked whether academic grant funding tone has changed and whether CapEx will differ for launch readiness.
A: They said tau early-access work falls into three buckets: mechanistic biology, disease biology/therapeutic-development studies, and biomarker discovery, with examples showing that different model systems have distinct tau proteoforms and that APOE genotype linked to specific phosphorylated tau forms. On funding, they said customers remain nervous about NIH funding and S10 grants are uncertain, but funding still seems to happen and Nautilus is less sensitive because it's early. On CapEx, they said cash runway into Q1 2028 supports investments in the proteoform portfolio, instrument launch, and commercial team; they expect CapEx to grow with spending but do not see material facility or equipment CapEx now and would only make targeted investments.
"When she was looking and studying them using our platform, it was clear immediately that they actually have very different forms of tau." — Parag Mallick (FOUNDER)
SEEDS samples, HUPO feedback, instrument usage
Q (Max Masucci · Roth Capital Partners): The analyst asked whether SEEDS will run tau in CSF or blood and how it advances biofluid work. He also asked what HUPO and early-access feedback changed in launch priorities and how much tau alone will drive early instrument usage versus needing multiple assays.
A: They said SEEDS work includes running existing tau assays in tissue samples, model systems, and biofluids, plus building a new assay for tissues and biofluids for an EWS-FLI1 cancer biomarker and further platform optimization. From HUPO and customers they heard that single-molecule proteoform measurement is unique and that priorities are increasing content (more proteins/proteoforms) and capabilities (sensitivity, lower sample input, new matrices like biofluids); those changes are addressed via consumables. They said at instrument ship they expect tau, AKT1, and another oncology assay in GA with more assays in early access, and that instruments become financially sensible versus services when customers reach about "$500,000 of consumable pull-through annually," which they expect will take time.
"It includes running our existing assays for tau in both tissue samples as well as model systems." — Parag Mallick (FOUNDER)